

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AIM Vaccine Co., Ltd.**

**艾美疫苗股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 06660)**

## **PROFIT WARNING**

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment by the Board of the Group’s unaudited consolidated management accounts for the year ended December 31, 2022 (the “**Year 2022**”) and the information currently available to the Board, the Group is expected to record an unaudited consolidated net loss ranging from RMB203.0 million to RMB270.0 million for the Year 2022, representing a decrease of approximately 60% to 70% compared to the net loss incurred for the year ended December 31, 2021 (the “**Year 2021**”).

The Board is of the preliminary view that the significant decrease in the Group’s net loss for the Year 2022 is primarily attributable to the considerable decrease in the Group’s overall expenses for the Year 2022 as compared to that for the Year 2021.

The information contained in this announcement is prepared only based on the information currently available to the Board and a preliminary assessment of the consolidated management accounts of the Group for the Year 2022 which have not been confirmed, reviewed or audited by the independent auditor of the Company. The audited results of the Group for the Year 2022 may differ from what is disclosed in this announcement. Shareholders and potential investors are advised to refer to the results announcement of the Group for the Year 2022 which is expected to be published in late March 2023.

**Meanwhile, Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**AIM Vaccine Co., Ltd.**  
**Mr. Yan ZHOU**  
*Chairman of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, March 3, 2023

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.*